Insight

Transforming Pharma: Harnessing Artificial Intelligence in the Pharmaceutical Value Chain

Mark Thever

Focus Area/Service

Life Sciences Advisory

The rise of artificial intelligence continues to transform the pharmaceutical industry, offering solutions to longstanding challenges across the value chain. As pharmaceutical companies embrace this technological revolution, organizations are implementing AI use cases that tackle critical issues in drug discovery, clinical trial development, and patient monitoring, opening doors to innovative approaches in pharmaceutical research and development.

A Dose of AI Efficiency for Pharma

The pharmaceutical industry’s complexity produces significant challenges — many of which can be addressed with AI.

High Costs: Bringing a drug to market can cost hundreds of millions to over $2 billion. These expenses stem from several factors including R&D, clinical trials, regulatory compliance, manufacturing, and commercialization. Each therapeutic area and individual drug candidate has unique requirements, resulting in significant cost variations.

Long Development Times: The average timeline from initial screening to commercialization is 10-15 years. This extended runway increases costs and impacts the usable patent life once the drug reaches the market. A patent is typically filed early in the R&D stage, providing 20 years of exclusivity. However, long development times can significantly reduce the patent-protected years on the market, directly impacting potential revenue.

Clinical Trial Coordination and Execution: Specific patient population requirements can limit the effectiveness of a clinical trial. For example, some drugs target rare diseases that affect extremely geographically dispersed populations with too few patients to easily achieve statistical significance.

Effective Patient Monitoring: Controlled trial environments may not reflect natural settings. This can make understanding how patients respond to therapies in real-time and real-life scenarios difficult.

These challenges create a pressing need for innovative solutions that can streamline processes, reduce costs, and accelerate drug development without compromising safety or efficacy. Leveraging the vast amounts of data generated daily, pharmaceutical organizations can use customized AI models to generate insights and predictions resulting in actionable initiatives such as:

Reduced time and cost for drug discovery and development,
Improved accuracy in predicting drug candidates and their properties,
Enhanced efficiency in clinical trials,
More comprehensive and objective patient monitoring, and
Potential for earlier patient access to life-saving therapies.

Quintuple Catalyst: 5 Instances of AI in Pharma

1. Early Drug Discovery

AI impacts early drug discovery in four select areas:

ai in pharma, drug discovery, four areas of interest

Virtual Screening: AI models can predict properties of drug candidates such as toxicity and binding affinity.

Synthesis Prediction: Algorithms forecast synthesis results and determine optimal synthetic routes (retrosynthesis). For instance, given ingredients A and B, the algorithm predicts the resultant product C, considering molecular shape, binding sites, and chemical properties.

Chemistry and Biology Modeling: AI predicts physiological interactions, helping users understand and predict the mechanism of action (MOA) of potential drug candidates. This is particularly valuable for drugs where the MOA is theorized but not fully elucidated.

Lead Optimization: Models generate new molecular structures based on desired biochemical input characteristics. For example, given a list of desired properties, an algorithm can predict new molecular structures exhibiting those characteristics.

These applications can potentially reduce the early drug discovery phase by up to 50 percent, from 3-6 years to 1.5-3 years. For patients, this grants earlier access to potentially life-saving therapies. For pharmaceutical organizations, this time reduction has significant implications for viable patent life on the market and revenue-driving years for the drug, underscoring the substantial value that AI imparts.

2. De Novo Drug Design

Small molecules — which comprise approximately 90 percent of drugs that come to market — can be generated through various methods. One method is de novo drug design, where theoretical molecules are created from scratch with no starting materials to edit or optimize. AI can facilitate this process.

Before a theoretical molecule can be created using AI, the algorithm must be trained on molecular characteristics and fit and function data related to biological targets. High Throughput Screening (HTS) data and 2D chemical structures serve as two potential data sources, conveying information about target binding, candidate efficacy, candidate stability, molecular binding dynamics, and putative function based on structure. Using this data, the trained model predicts:

What structural element to add next,
Which part of the added element needs to bind, and
Where to attach the new element to the forming structure.

In this way, AI can systematically construct a theoretical molecule based on the provided inputs, defining the desired traits of the resultant molecule.

3. Antibody Optimization

For biologics, which are larger, more structurally complex molecules typically manufactured from living organisms, AI can assist in the antibody optimization process.

The goal of antibody optimization is to design new Complementarity Determining Regions (CDRs) that are specific to a particular biological target. AI optimizes several features including:

Affinity: How well the antibody binds
Neutralization: If it binds to the correct target
Specificity: How specifically it binds the target of interest without binding unintended targets
Stability: The overall stability of the antibody

The process involves training a model on existing antibody CDRs and their targets. The model can then start with an existing antibody digital structure, strip the existing CDR, replace it with a theoretical CDR structure specific to the desired characteristics, and generate theoretical antibody candidates with customized CDRs. This procedure can be iterated to create more specific antibodies to targets of interest.

4. Clinical Trial Optimization

While Randomized Clinical Trials (RCTs) remain the gold standard, they have several limitations including:

Group Discrepancies: Despite random assortment, chance variability in baseline characteristics can result in dissimilar groups, introducing bias.

Inadequate Population Representation: Strict eligibility criteria may result in a study population that does not accurately represent real-world patients.

Statistical Power Challenges: Achieving adequate statistical power with small group sizes can be difficult, especially for rare diseases.

AI can alleviate these limitations by optimizing the design, planning, and management of clinical trials. More specifically, AI can predict patient responses to create more homogeneous trial groups, refine inclusion criteria for better population representation, and project investigational therapy effects on certain patients. This enables pharmaceutical organizations to operate on expected outcomes, achieve statistical power with smaller sample sizes, shorten trial execution periods, and lower associated costs.

5. Patient Monitoring

Traditional patient monitoring faces several challenges, including a high degree of subjectivity in patient self-reporting, difficulty distinguishing slow vs. fast-progressing diseases, and limitations in data collection locations (e.g., in-clinic only).

AI-enabled patient monitoring through wearable and ambient devices offers several advantages:

Continuous, objective data collection in real-world settings,
Reduced subjectivity in symptom reporting,
More accurate detection of disease progression or therapy response, and
Potential for remote monitoring, reducing the need for in-clinic visits.

AI algorithms analyze this continuous data to recognize disease severity or stage, potentially improving diagnosis and treatment for conditions like Facioscapulohumeral Muscular Dystrophy (FSHD) and Parkinson’s Disease.

For instance, in sleep studies, AI motion tracking can replace traditional sleep lab observations. Without the need for wearables, patients can be monitored at home and experience unencumbered sleep in a natural, comfortable environment. This enables continuous and passive data collection, offering a more comprehensive view of sleep patterns over time. This method not only improves patient comfort and convenience but also enhances the quality and quantity of data available for analysis, potentially leading to more accurate diagnoses and effective treatments for sleep disorders.

These benefits result in reduced trial costs, greater objectivity, and larger datasets for predictive decision-making.

Limitations of AI in Pharma

AI offers powerful and versatile applications, but we must consider its limitations. AI algorithms can produce hallucinations — nonsensical or inaccurate outputs based on non-existent patterns — when fed noisy or biased data, influenced by hidden variables, or structured as overly complex models.

Bias presents another challenge. AI models can generate biased outputs due to numerous factors: lack of diversity in training data, unclean or subjective data, poor annotations, flawed model construction, or mismatched query and training sets. These issues underscore the critical need for high-quality, diverse data and rigorous validation, testing, and ongoing monitoring of deployed algorithms.

Conclusion

The pharmaceutical industry stands at an inflection point. AI has the power to transform the entire value chain, from drug discovery to patient care. However, realizing this potential requires careful planning, ethical considerations, and a commitment to responsible AI use. As the field evolves, those who successfully integrate AI into their processes will likely gain a significant competitive advantage in the rapidly changing landscape of pharmaceutical development.

The future of pharma is here, and it’s powered by AI. By embracing these technologies and addressing the associated challenges head-on, the industry can usher in a new era of drug discovery and development, ultimately improving patient outcomes and transforming healthcare as we know it.

Explore Acquis’ Life Sciences Advisory Capabilities →